The Breast Cancer 21 Gene Test is more accurate. The Breast Cancer 21 Gene Test is a test that detects the expression levels of 21 different genes in breast cancer tumor tissues, which include 16 breast cancer-related genes and 5 reference genes. The test can provide individualized treatment outcome prediction and 10-year risk of recurrence. By detecting 21 genes in breast tumors and observing their interactions to determine tumor characteristics, it can predict individualized breast tumor recurrence index and benefit ratio of receiving chemotherapy. The lower the patient’s recurrence index, the lower the chance of breast cancer recurrence and the less likely the patient will benefit from chemotherapy. The data after genetic testing is more accurate, and 21-gene testing for breast cancer patients will indeed bring great benefits in treatment, allowing treatment to be more targeted to patients by adjusting the direction at any time based on the testing data. In addition, 21-gene testing is recommended for certain patients, but not all patients need to have genetic testing, which should be decided in conjunction with the patient’s postoperative pathological stage.